Webinar :Register now for webinar on 'Trade BankNifty in just 15 minutes a day' - By Asmita Patel
you are here: HomeNewsIndia
Last Updated : Oct 23, 2020 08:23 PM IST | Source: Moneycontrol.com

Bharat Biotech's Covaxin receives approval for Phase III trials: Reports

The approval was reportedly given after assessing data from Phase I and II and animal challenge study.


Bharat Biotech's coronavirus vaccine Covaxin has received approval for carrying out Phase III trials on October 22, reports suggest.

The approvals were reportedly given after assessing data from Phase I and II and animal challenge study.

Phase III is likely to start next month, Business Today reported. The report said an expert committee met on October 20 to give its nod to Phase III trials and suggested some 'minor amendments' in the protocol.

Close

Bharat Biotech had applied to the Drugs Controller General of India (DCGI) seeking permission for the crucial Phase III of trials on October 2, NDTV reported.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

In its application, the firm said the study would cover over 28,500 subjects, aged 18 years and above. The study would be conducted at 19 sites in 10 states across the country, the report said.

The potential vaccine against COVID-19 is being developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

Click here for Moneycontrol's COVID-19 Vaccine Watch

Phase I of Covaxin’s clinical trial involved 375 volunteers. Interim data from Phase I has not been made public yet.

Two doses of the Covaxin vaccine candidate are to be administered with a gap of 14 days between them.
First Published on Oct 22, 2020 10:10 pm
Sections